Table 1.
Feature | In-silico model | Classification | References | NTotal | NCorrect | |
---|---|---|---|---|---|---|
TDP+ | TDP− | |||||
NA | Feature < 30 | Feature > 30 | Redfern et al., 2003 | 52 | NA | |
APD90 | Ventricular myocyte models of rabbit, rat and human | LDA | Mirams et al., 2011 | 31 | 30 | |
NA | LR | Kramer et al., 2013 | 55 | 50 | ||
NA | LR | Mistry et al., 2015 | 31 from (Mirams et al., 2011) 55 from (Kramer et al., 2013) |
28 | ||
TDR | Human ventricular myocyte model | TDR profiles | Christophe, 2015 | 55 from (Kramer et al., 2013) |
NA | |
3D FEM model of human heart | Feature < 200 | Feature > 200 | Okada et al., 2015 | 12 | 12 | |
EADs | Human ventricular myocyte model | Waveform appearance | Abbasi et al., 2017 | 12 from (Okada et al., 2015) |
11 | |
APD50 & Diastolic Ca2+ | Human ventricular myocyte models | SVM and PCA | Lancaster and Sobie, 2016 | 86 from (Kramer et al., 2013) and (Mirams et al., 2011) |
75 | |
Human ventricular myocyte model | LDA | Li et al., 2017 | 12 | 12 |
LDA, Linear Determinant Analysis; LR, Logistic Regression; SVM, Support Vector Machine; PCA, Principal Component Analysis; Cdrug,EAD, concentration of the drug that produces EAD; BPx, % block of the x (x = Na, fast, CaV, hERG) ion channels; TDR, transmural dispersion of repolarization; Cdrug,Arrhythmia, concentration of the drug that produces arrhythmia in the model; EAD, early after depolarizations; AUCIx,drug/control, area under the curve of the x (x = CaV, NaL) current transient at steady state action potential in the presence (drug) or absence of the drug (control). Table also lists the number of compounds analyzed in the study (NTotal) and the number of correctly classified compounds (Ncorrect).